AstraZeneca announced plans to initiate a Phase 3 trial for rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific antibody, and is also developing an expanded Phase 2 program. COM902, Compugen’s high-affinity anti-TIGIT antibody was licensed in 2018 to AstraZeneca for exclusive use in bi-specific and multi-specific antibody products, excluding PVRIG- and/or PVRL2- TIGIT-bispecific products
Nasdaq Down 90 Points; DLocal Shares Spike Higher
U.S. stocks traded mostly lower midway through trading, with the Nasdaq Composite declining around 90 points on Wednesday.
The Dow traded down 0.01% to 34,942.88 while the NASDAQ fell 0.67% to 13,540.33. The S&P 500, also fell, dropping, 0.20% to 4,428.93.
